Article
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2020
Shi Yuankai, Zhang Shucai, Hu Xingsheng, Feng Jifeng, Ma Zhiyong, Zhou Jianying, Yang Nong, Wu Lin, Liao Wangjun, Zhong Dafang, Han Xiaohong, Wang Ziping, Zhang Xiaodong, Qin Shukui, Ying Kejing, Feng Jian, Fang Jian, Liu Li, Jiang Yong
Abstract excerpt
INTRODUCTION: Alflutinib (AST2818) is a newly developed third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M-resistant mutations. We assessed the safety, efficacy, and pharmacokinetics of alflutinib in patients with advanced NSCLC with confirmed EGFR T790M mutation, whose status progressed after the first- or second-generation EGFR tyrosine kinase inhibitor therapy. METHODS: In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.